Human Immunodeficiency Virus  >>  Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) / J&J, Gilead
NCT02993237 / 2016-003016-12: Study to Assess the Acceptability/Swallowability of DRV-Containing FDC Tablets in HIV-1 Infected Adolescents, Using Matching Placebo Tablets

Completed
1
27
US
DRV/COBI FDC placebo tablet, D/C/F/TAF FDC placebo tablets
Janssen Research & Development, LLC
HIV-1
05/17
05/17
NCT04006704 / 2019-001384-68: Study to Assess the Acceptability of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed-Dose Combination (FDC) Tablets in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Pediatric Participants, Using Matching Placebo Tablets

Completed
1
25
Europe, US
D/C/F/TAF FDC placebo
Janssen Pharmaceutica N.V., Belgium
HIV-1
03/20
03/20

Download Options